New regulatory mechanism of satiety and therapeutic target for obesity

To understand the mechanism by which MT1-MMP suppresses GDF15 satiety signalling, the research team conducted a series of molecular biology experiments involving animal models and cell cultures. The results show that in cells with active MT1-MMP, a significant reduction of GFRAL and thus GDF15 signalling was observed. It could be explained by MT1-MMP clipping GFRAL from the surface of the brain neurons, which blocks GDF15 from binding to GFRAL and thus reduces the number of satiety signals. This in turn keeps the neurons from transmitting the satiety signals sent by GDF15.

The researchers also explored the therapeutic potential of targeting MT1-MMP for obesity management, in particular through pharmacological inhibition of its activity in vivo. With the application of a specific neutralising antibody that inhibits MT1-MMP, significant improvements in metabolic parameters including food intake, glucose tolerance and body weight in obese mice were observed. The results suggest that MT1-MMP is a potential therapeutic target that could be used in the development of innovative drug treatments for obesity.

This significant finding highlights the potential of targeting MT1-MMP as a therapeutic strategy for obesity. Inhibiting this enzyme may help regulate appetite and control body weight, offering a promising new approach to treating obesity and related health issues. Our research team plans to validate these findings in a monkey model, bringing us closer to developing effective obesity treatments for humans. This discovery offers new hope for millions struggling with obesity and its associated health risks, paving the way for innovative therapies that could transform lives.